Mucin expression profile of benign and malignant cervical tissues and correlation with clinical-pathologic parameters

Purpose: To detect the expression of mucins in diverse benign and malignant cervical tissues of cervical disease. Materials and Methods: 158 cases of cervical tissues were collected. Sections were stained with monoclonal antibodies against MUC1, MUC2, MUC4, MUC5AC, and MUC20 by immunohistochemistry. Results: Normal cervical epithelium showed high expression of MUC1, MUC4, and MUC5AC, partial expression of MUC20, and no MUC2. With the development from chronic cervicitis, cervical intraepithelial neoplasia (CIN) to cervical squamous cell carcinoma (SCC), the expression of MUC1, MUC4, and MUC20 was statistically significant. The expression of MUC1 was related with the depth of invasion and clinical stage of SCC. The positive rates of MUC4 and MUC20 were associated with the degree of differentiation and clinical stage of SCC. There was a correlation between the expression of MUC4, MUC1, and MUC20 in cervical squamous lesions. Conclusion: Mucins may be involved in the development of cervical cancer.

Mucin; Cervical intraepithelial neoplasia (CIN); Squamous cell carcinoma (SCC); Adenocarcinoma; Clinical-pathologic parameters; Immunohistochemistry.

[1] Togami S., Nomoto M., Higashi M., Goto M., Yonezawa S., Tsuji T., et al.: “Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix”. J. Obstet. Gynaeco.l Res., 2010, 36, 588.

[2] Maischberger E., Cummins C.A., Fitzpatrick E., Gallagher M.E., Worrall S., Rousseau K., et al.: “The expression of mucin genes and the presence of mucin gene products in the equine endometrium”. Res. Vet. Sci. ,2013, 95, 169.

[3] Wang J., El-Bahrawy M.: “Expression profile of mucins (MUC1, MUC2, MUC5AC, and MUC6) in ovarian mucinous tumours: changes in expression from benign to malignant tumours”. Histopathology, 2015, 66, 529.

[4] Baker A.C., Eltoum I., Curry R.O., Stockard C.R., Manne U., Grizzle W.E., Chhieng D.: “Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix”. Arch. Pathol. Lab. Med., 2006, 130, 1510.

[5] Corfield A.P.: “Mucins: a biologically relevant glycan barrier in mucosal protection”. Biochim. Biophys. Acta, 2015, 1850, 236.

[6] Manne U., Weiss H.L., Grizzle W.E.: “Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas”. Clin. Cancer Res., 2000, 6, 4017.

[7] Mukhopadhyay P., Chakraborty S., Ponnusamy M.P., Lakshmanan I., Jain M., Batra S.K.: “Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy”. Biochim. Biophys. Acta, 2011, 1815, 224.

[8] Cai H., Palitzsch B., Hartmann S., Stergiou N., Kunz H., Schmitt E., Westerlind U.: “Antibody induction directed against the tumor-associated MUC4 glycoprotein”. Chembiochem., 2015, 16, 959.

[9] Higuchi T., Orita T., Nakanishi S., Katsuya K., Watanabe H., Yamasaki Y., et al.: “Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney”. J. Biol. Chem., 2004, 279, 1968.

[10] Gipson I.K., Ho S.B., Spurr-Michaud S.J., Tisdale A.S., Zhan Q., Torlakovic E., et al.: “Mucin genes expressed by human female reproductive tract epithelia”. Biol. Reprod., 1997, 56, 99.

[11] Gipson I.K., Spurr-Michaud S., Moccia R., Zhan Q., Toribara N., Ho S.B., et al.: “MUC4 and MUC5B transcripts are the prevalent mucin messenger ribonucleic acids of the human endocervix”. Biol. Reprod., 1999, 60, 58.

[12] Vinh-Hung V., Bourgain C., Vlastos G., Cserni G., De Ridder M., Storme G., Vlastos A.T.: “Prognostic value of histopathology and trends in cervical cancer: a SEER population study”. BMC Cancer, 2007, 7, 164.

[13] Houghton O., Jamison J., Wilson R., Carson J., McCluggage W.G.: “p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection”. Histopathology, 2010, 57, 342.

[14] Mikami Y., McCluggage W.G.: “Endocervical glandular lesions exhibiting gastric differentiation: an emerging spectrum of benign, premalignant, and malignant lesions”. Adv. Anat. Pathol., 2013, 20, 227.

[15] Audie J.P., Tetaert D., Pigny P., Buisine M.P., Janin A., Aubert J.P., et al.: “Mucin gene expression in the human endocervix”. Hum. Reprod., 1995, 10, 98.

[16] Riethdorf L., O’Connell J.T., Riethdorf S., Cviko A., Crum C.P.: “Differential expression of MUC2 and MUC5AC in benign and malignant glandular lesions of the cervix uteri”. Virchows Arch., 2000, 437, 365.

[17] Zhao S., Hayasaka T., Osakabe M., Kato N., Nakahara K., Kurachi H., et al.: “Mucin expression in nonneoplastic and neoplastic glandular epithelia of the uterine cervix”. Int. J. Gynecol. Pathol, 2003, 22, 393.

[18] Lau S.K., Weiss L.M., Chu P.G.: “Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study”. Am. J. Clin. Pathol., 2004, 122, 61.

[19] Terada T.: “Coexistence of early microinvasive endometrioid adenocarcinoma and CIN3 in the uterine cervix in a 32-year-old Japanese woman”. Diagn. Pathol., 2011, 6, 51.

[20] Mitsuhashi A., Yamazawa K., Nagai Y., Tanaka N., Matsui H., Sekiya S.: “Correlation between MUC5AC expression and the prognosis of patients with adenocarcinoma of the uterine cervix”. Ann. Surg. Oncol., 2004, 11, 40.

[21] Munro E.G., Jain M., Oliva E., Kamal N., Lele S.M., Lynch M.P., et al.: “Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance”. Int. J. Gynecol. Pathol., 2009, 28, 127.

[22] Lopez-Ferrer A., Alameda F., Barranco C., Garrido M., de Bolos C.: “MUC4 expression is increased in dysplastic cervical disorders”. Hum. Pathol., 2001, 32, 1197.

[23] Higuchi T., Orita T., Katsuya K., Yamasaki Y., Akiyama K., Li H., et al.: “MUC20 suppresses the hepatocyte growth factor-induced Grb2- Ras pathway by binding to a multifunctional docking site of met”. Mol. Cell. Biol., 2004, 24, 7456.

[24] Xiao X., Wang L., Wei P., Chi Y., Li D., Wang Q., et al.: “Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer”. J. Transl. Med., 2013, 11,151.

[25] Chen C.H., Wang S.W., Chen C.W., Huang M.R., Hung J.S., Huang H.C., et al.: “MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer”. Gynecol. Oncol., 2013, 128, 560.

[26] Tarang S., Kumar S., Batra S.K.: “Mucins and toll-like receptors: kith and kin in infection and cancer”. Cancer Lett., 2012, 321, 110.